| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents
|
MEHTA, R.
|
|
2006
|
12 |
s6 |
p. 54-61
|
article
|
| 2 |
Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors
|
ULLMAN, M.
|
|
2006
|
12 |
s6 |
p. 74-80
|
article
|
| 3 |
Basic aspects of bypassing agents
|
NEGRIER, C.
|
|
2006
|
12 |
s6 |
p. 48-53
|
article
|
| 4 |
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors
|
ASTERMARK, J.
|
|
2006
|
12 |
s6 |
p. 8-14
|
article
|
| 5 |
Characteristics of inhibitors in mild/moderate haemophilia A
|
PEERLINCK, K.
|
|
2006
|
12 |
s6 |
p. 43-47
|
article
|
| 6 |
CME Assessment Test and Activity Evaluation
|
|
|
2006
|
12 |
s6 |
p. v-vi
|
article
|
| 7 |
Genetic risk factors for inhibitors to factors VIII and IX
|
OLDENBURG, J.
|
|
2006
|
12 |
s6 |
p. 15-22
|
article
|
| 8 |
Immune tolerance: critical issues of factor dose, purity and treatment complications
|
DIMICHELE, D. M.
|
|
2006
|
12 |
s6 |
p. 81-86
|
article
|
| 9 |
Immunological aspects of inhibitor development
|
REDING, M. T.
|
|
2006
|
12 |
s6 |
p. 30-36
|
article
|
| 10 |
Inhibitor treatment in haemophilias A and B: inhibitor diagnosis
|
DIMICHELE, D. M.
|
|
2006
|
12 |
s6 |
p. 37-42
|
article
|
| 11 |
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference
|
BERNTORP, E.
|
|
2006
|
12 |
s6 |
p. 1-7
|
article
|
| 12 |
Novel therapies for immune tolerance in haemophilia A
|
COLLINS, P. W.
|
|
2006
|
12 |
s6 |
p. 94-101
|
article
|
| 13 |
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics
|
BERNTORP, E.
|
|
2006
|
12 |
s6 |
p. 62-66
|
article
|
| 14 |
Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders
|
KOMVILAISAK, P.
|
|
2006
|
12 |
s6 |
p. 87-93
|
article
|
| 15 |
Program Faculty
|
|
|
2006
|
12 |
s6 |
p. iii
|
article
|
| 16 |
Prophylaxis in haemophilia patients with inhibitors
|
LEISSINGER, C. A.
|
|
2006
|
12 |
s6 |
p. 67-73
|
article
|
| 17 |
Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
|
ETTINGSHAUSEN, C. ESCURIOLA
|
|
2006
|
12 |
s6 |
p. 102-106
|
article
|
| 18 |
Sponsorship and CME Credit
|
|
|
2006
|
12 |
s6 |
p. iv
|
article
|
| 19 |
The epidemiology of factor VIII inhibitors
|
HAY, CHARLES R. M.
|
|
2006
|
12 |
s6 |
p. 23-29
|
article
|
| 20 |
Urgent inhibitor issues: targets for expanded research
|
HOOTS, W. K.
|
|
2006
|
12 |
s6 |
p. 107-113
|
article
|
Journal description